VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | AML: what to look forward to at ASH 2020

Thomas Prebet, MD, PhD, Yale School of Medicine, New Haven, CT, outlines what he’s looking forward to at this year’s virtual ASH conference. This includes greater insight into the management of molecularly-defined disease and new agents that are rising as potentially active treatments for acute myeloid leukemia (AML). This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Thomas Prebet, MD, PhD, has done consultancy work for BMS and AbbVie and has received research support from BMS and Jazz.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter